ZYME Stock Analysis: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$22.53
0.15 (0.67%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 04, 2026
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ZYME this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZYME shows positive signals but monitor for confirmation. Market pricing in 12.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ZYME shows positive signals but monitor for confirmation. Market pricing in 12.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.44
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$7.10
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $22.53, which is considered oversold relative to its 30-day fair value range of $22.87 to $26.15. From a valuation perspective, the stock is trading at a discount (Forward PE: 68.5) compared to its historical average (103.2). Remarkably, the market is currently pricing in an annual earnings decline of 12.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is in a strong uptrend. The price is currently testing key support at $22.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.62 (+59.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZYME is in a strong uptrend. The price is currently testing key support at $22.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.62 (+59.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$22.87 -
$26.15
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.1% below Wall St target ($35.62)
Fair Price Analysis
30-Day Fair Range
$22.87 -
$26.15
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.20
(9.8%)
Support & Resistance Levels
Support Level
$22.08
Resistance Level
$24.31
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
68.52
Wall Street Target
$35.62
(+59.1%)
Revenue Growth (YoY)
72.6%
Profit Margin
-47.2%
Valuation Discount vs History
-12.8% cheaper
PE vs Historical
68.5 vs 103.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.8%
(market-implied from PE analysis)
1-Year Target
$20.14
(-10%)
2-Year Target
$18.13
(-19%)
3-Year Target
$16.32
(-27%)
3-Yr Target (if PE normalizes)
(PE: 69→103)
$24.57
(+10%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 68.5 to 103.2
Stabilization Target:
$33.71
(+50.6%)
PE Expansion Potential:
+50.6%
Last updated: January 30, 2026 7:33 PM ET
Data refreshes hourly during market hours. Next update: 8:33 PM
Data refreshes hourly during market hours. Next update: 8:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
